Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:26:21 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:DYN - DYNE THERAPEUTICS INC - https://www.Dynegy.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
DYN - Q1.015.50·16.850.316.80+0.251.51,422.122,90715,50817.09  17.49  16.4025.00  6.3617:51:28Jan 2015 min RT 2¢

Recent Trades - Last 10 of 15508
Time ETExPriceChangeVolume
17:51:28Q16.950.4010
17:31:53Q16.960.4140
17:07:17Q16.92020.3702100
17:03:37Q17.000.457
17:02:55Q16.98250.43254
17:01:39Q16.98250.43254
16:39:07Q16.850.301
16:15:43Q16.960.41400
16:10:04Q16.800.251
16:10:04Q16.800.251

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-20 07:30U:DYNNews ReleaseDyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
2026-01-07 07:30U:DYNNews ReleaseDyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
2025-12-23 07:30U:DYNNews ReleaseDyne Therapeutics Appoints Vikram Karnani to Board of Directors
2025-12-11 16:05U:DYNNews ReleaseDyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
2025-12-09 21:43U:DYNNews ReleaseDyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
2025-12-08 16:02U:DYNNews ReleaseDyne Therapeutics Announces Proposed Public Offering of Common Stock
2025-12-08 06:30U:DYNNews ReleaseDyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
2025-12-07 11:00U:DYNNews ReleaseDyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
2025-11-05 16:10U:DYNNews ReleaseDyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
2025-11-03 07:30U:DYNNews ReleaseDyne Therapeutics to Present at Upcoming Investor Conferences
2025-10-06 18:01U:DYNNews ReleaseDyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
2025-10-02 16:05U:DYNNews ReleaseDyne Therapeutics Appoints Brian Posner to its Board of Directors
2025-09-29 08:35U:DYNNews ReleaseDyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
2025-08-27 07:30U:DYNNews ReleaseDyne Therapeutics to Present at Upcoming Investor Conferences
2025-08-04 07:30U:DYNNews ReleaseDyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)
2025-07-28 16:10U:DYNNews ReleaseDyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
2025-07-02 16:01U:DYNNews ReleaseDyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
2025-06-30 21:45U:DYNNews ReleaseDyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock
2025-06-30 16:05U:DYNNews ReleaseDyne Therapeutics Announces Proposed Public Offering of Common Stock
2025-06-30 16:01U:DYNNews ReleaseDyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital